Discovery of Novel (Imidazo[1,2-a]pyrazin-6-yl)ureas as Antiproliferative Agents Targeting P53 in Non-small Cell Lung Cancer Cell Lines

Anticancer Res. 2016 Apr;36(4):1621-30.

Abstract

A series of (imidazo[1,2-a]pyrazin-6-yl)ureas were synthesized through 6-aminoimidazo[1,2-a]pyrazine as a key intermediate. 1-(Imidazo[1,2-a]pyrazin-6-yl)-3-(4-methoxy - phenyl)urea displayed a cytostatic activity against a non-small cell lung cancer cell line and was chosen for further mechanistic studies. Growth kinetics highlighted a selective dose-dependent response of P53-mutant NSCLC-N6-L16 cell line and overexpression of TP53 gene induced by this compound. These pharmacological data suggest a promising reactivation of p53 mutant in NSCLC-N6-L16 cell line.

Keywords: Imidazo[1,2-a]pyrazine; NSCLC; antiproliferative activity; p53; urea.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • BALB 3T3 Cells
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Humans
  • Imidazoles / pharmacology*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Mice
  • Pyrazines / pharmacology*
  • Tumor Suppressor Protein p53 / genetics
  • Urea / analogs & derivatives*
  • Urea / pharmacology*

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Pyrazines
  • Tumor Suppressor Protein p53
  • Urea